Argenx has been granted a patent for bispecific antigen binding constructs that combine a single domain antibody (VHH) with IgG Fc domains. These constructs can target two different antigens, enhancing therapeutic potential through their unique design and dimerization properties. GlobalData’s report on Argenx gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Argenx, Personalized cancer vaccines was a key innovation area identified from patents. Argenx's grant share as of July 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
Bispecific antigen binding constructs targeting two different antigens
The granted patent US12071486B2 describes a bispecific antigen binding construct that combines a single VHH domain from a heavy-chain-only antibody and a single Fab portion from a conventional IgG antibody. The VHH domain is designed to bind to a first target antigen and is fused to the N-terminus of a human IgG1 Fc domain polypeptide. In parallel, the Fab portion, which targets a second antigen, is also fused to a second human IgG1 Fc domain polypeptide. Notably, the two IgG1 Fc domain polypeptides are engineered to dimerize through knobs-into-holes interactions, enhancing the stability and functionality of the construct. Specific amino acid configurations at certain EU positions (366, 368, and 407) in the Fc domains are also detailed, indicating a precise design for optimal binding and interaction.
Additionally, the patent claims a pharmaceutical composition that incorporates this bispecific antigen binding construct. It specifies that the conventional IgG antibody can be derived from the immunization of a Camelidae family animal with the second target antigen. The bispecific construct is characterized by a molecular weight ranging from approximately 100 kDa to 120 kDa, which is relevant for its potential therapeutic applications. This innovative design aims to improve the efficacy of targeting multiple antigens simultaneously, which could have significant implications in the treatment of various diseases.
To know more about GlobalData’s detailed insights on Argenx, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
